National Guideline Clearinghouse | Plerixafor for autologous hematopoietic stem cell mobilization and transplantation for patients in Ontario.

National Guideline Clearinghouse | Plerixafor for autologous hematopoietic stem cell mobilization and transplantation for patients in Ontario.

Program in Evidence-based Care

• Plerixafor for autologous hematopoietic stem cell mobilization and transplantation for patients in Ontario.

Guideline Title Plerixafor for autologous hematopoietic stem cell mobilization and transplantation for patients in Ontario. Bibliographic Source(s) Kouroukis CT, Varela NP, Bredeson C, Kuruvilla J, Xenocostas A, Stem Cell Transplant Steering Committee. Plerixafor for autologous hematopoietic stem cell mobilization and transplantation for patients in Ontario. Toronto (ON): Cancer Care Ontario (CCO); 2015 Sep 15. 45 p. (Evidence-based series; no. SCT-7).  [33 references] Guideline Status This is the current release of the guideline. The EVIDENCE-BASED SERIES report, initially the full original Guideline, over time will expand to contain new information emerging from their reviewing and updating activities. Please visit the Cancer Care Ontario (CCO) Web site  for details on any new evidence that has emerged and implications to the guidelines This guideline meets NGC's 2013 (revised) inclusion criteria.